Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer

Pathology

Volumn 44, Issue 6, 2012, Pages 513-518

  Mills, John ^a,b   Oliver, Alice ^a,g   Sherwin, Justin C ^a,g   Frydenberg, Mark ^b   Peters, Justin S ^c   Costello, Anthony ^c   Harewood, Laurence ^d   Love, Christopher ^e   Redgrave, Nicholas ^e   Van Golen, Kenneth L ^b   Bailey, Michael ^f   Pedersen, John ^a,b  

^a Tissupath Pty Ltd   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Epworth Hospital   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Bayside Urology   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g UNIVERSITY OF DELAWARE   (United States)

Author keywords

AZGP 1 (ZAG) protein; Prognosis; Prostate cancer; Prostatectomy; RhoC protein

Indexed keywords

EID: 84866930285     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e3283581780     Document Type: Article

References (29)

1. Ellenbroek SI, Collard JG. Rho GTPases: functions and association with cancer. Clin Exp Metastasis 2007; 24: 657-72.
2. Islam M, Lin G, Brenner JC, et al. RhoC expression and head and neck cancer metastasis. Mol Cancer Res 2009; 7: 1771-80.
3. Liu N, Zhang G, Bi F, et al. RhoC is essential for the metastasis of gastric cancer. J Mol Med 2007; 85: 1149-56.
4. Zhang HZ, Liu JG, Wei YP, et al. Expression of G3BP and RhoC in esophageal squamous carcinoma and their effect on prognosis. World J Gastroenterol 2007; 13: 4126-30.
5. Bokobza SM, Ye L, Kynaston H, Jiang WG. Growth and differentiation factor 9 (GDF-9) induces epithelial-mesenchymal transition in prostate cancer cells. Mol Cell Biochem 2011; 349: 33-40.
6. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406: 532-5.
7. Faried A, Faried LS, Kimura H, et al. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 2006; 42: 1455- 65.
8. Yuan Z, Su J, You JF, et al. Correlation of expression of RhoC with invasiveness of prostate cancer cell line PC-3M in vitro. (Chinese). Zhonghua Yi Xue Za Zhi 2008; 88: 51-5.
9. Vega FM, Fruhwirth G, Ng T, Ridley AJ. RhoA and RhoC have distinct roles in migration and invasion by acting through different targets. J Cell Biol 2011; 193: 655-65.
10. Hall CL, Dubyk CW, Riesenberger TA, et al. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 2008; 10: 797-803.
11. Sequeira L, Dubyk CW, Riesenberger TA, et al. Rho GTPases in PC-3 prostate cancer cell morphology, invasion and tumor cell diapedesis. Clin Exp Metastasis 2008; 25: 569-79.
12. Yao H, Dashner EJ, van Golen CM, van Golen KL. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 2006; 25: 2285-96.
13. Chatterjee M, Sequeira L, Jenkins-Kabaila M, et al. Individual rac GTPases mediate aspects of prostate cancer cell and bone marrow endothelial cell interactions. J Signal Transduct 2011; 2011: 541851.
14. Iiizumi M, Bandyopadhyay S, Pai SK, et al. RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res 2008; 68: 7613-20.
15. Byrne JC, Downes MR, O'Donoghue N, et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009; 8: 942-57.
16. Descazeaud A, de la Taille A, Allory Y, et al. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006; 66: 1037-43.
17. Henshall SM, Horvath LG, Quinn DI, et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98: 1420-4.
18. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101: 811-6.
19. Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: The impact of time from surgery to recurrence. Eur Urol 2011; 59: 893-9.
20. Kawata H, Shimada N, Kamiakito T, et al. RhoC and guanine nucleotide exchange factor Net1 in androgen-unresponsive mouse mammary carcinoma SC-4 cells and human prostate cancer after short-term endocrine therapy. Prostate 2012; 72: 1071-9.
21. Kleer CG, van Golen KL, Zhang Y, et al. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 2002; 160: 579-84.
22. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164: 217-27.
23. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
24. Han G, Buchanan G, Ittmann M, et al. Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci USA 2005; 102: 1151-6.
25. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-8.
26. Kondo T, Sentani K, Oue N, et al. Expression of RhoC is associated with metastasis of gastric carcinomas. Pathobiology 2004; 71: 19-25.
27. Hakem A, Sanchez-Sweatman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005; 19: 1974-9.
28. Wang W, Yang LY, Huang GW, et al. Overexpression of the RhoC gene correlates with invasion and metastasis of hepatocellular carcinoma. (Chinese). Zhonghua Zhong Liu Za Zhi 2004; 26: 279-82.
29. Planche A, Bacac M, Provero P, et al. Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer. PLoS One 2011; 6: e18640.